Pardoprunox is primarily investigated for its potential therapeutic applications in the treatment of neurological and psychiatric disorders. It acts as a partial dopamine agonist and serotonin receptor agonist, making it particularly relevant for conditions like Parkinson's disease and schizophrenia. In Parkinson's disease, it may help alleviate motor symptoms by modulating dopamine levels in the brain, improving movement control. For schizophrenia, its dual action on dopamine and serotonin receptors could contribute to reducing both positive symptoms, such as hallucinations, and negative symptoms, like social withdrawal. Additionally, its unique pharmacological profile suggests it may have a lower risk of side effects, such as dyskinesias, compared to other treatments. Research continues to explore its efficacy and safety in these and other potential applications.